Drug Profile
ChAdOx1 MERS vaccine - Barinthus Biotherapeutics
Alternative Names: ChAdOx1 MERS vaccine; MERS vaccine - Barinthus Biotherapeutics; MERS-CoV vaccine – Barinthus Biotherapeutics; VTP-500Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator Korea Investment Partners; Vaccitech
- Developer Barinthus Biotherapeutics; University of Oxford
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Middle East respiratory syndrome coronavirus
Most Recent Events
- 17 Jul 2023 Vaccitech plans a phase II trial for Middle East respiratory syndrome coronavirus (Vaccitech pipeline, July 2023)
- 24 Mar 2023 Phase- I development is ongoing in Saudi Arabia and UK (Vaccitech pipeline, March 2023)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in Saudi Arabia (IM)